Literature DB >> 2424853

Ocular neovascularization. Experimental animal model and studies on angiogenic factor(s).

S S Hayreh, G F Lata.   

Abstract

We have been investigating experimentally the factors which initiate and perpetuate ocular neovascularization (NV). Our studies can be divided into four categories: production of a primate experimental model of ocular NV, morphological studies, tissue culture studies, and biochemical studies. We have been successful in producing a reliable primate model of ocular NV following retinal vein occlusion (RVO). The morphological and fluorescein angiographic studies have established that the new vessels seen in the animal model represent true NV and not simple dilatation of the pre-existing vessels. The tissue culture studies have shown the presence of vasoproliferative activity in the intraocular fluids in eyes with ocular NV in our animal model. The various biochemical studies conducted so far have provided preliminary results on various aspects, including the protein electrophoretic pattern and lysosomal enzymes in the intraocular fluids from eyes with and without ocular NV and effects of anoxia and of corticosteroids. The results of our various studies are very briefly reviewed and the importance of angiogenesis is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424853     DOI: 10.1007/bf00159839

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  38 in total

1.  Ocular hypotony after retinal vascular occlusion.

Authors:  S S Hayreh; W March; C D Phelps
Journal:  Trans Ophthalmol Soc U K       Date:  1977-09

2.  Angiogenesis induced by degradation products of hyaluronic acid.

Authors:  D C West; I N Hampson; F Arnold; S Kumar
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

3.  Lipid angiogenic factor from omentum.

Authors:  H S Goldsmith; A L Griffith; A Kupferman; N Catsimpoolas
Journal:  JAMA       Date:  1984-10-19       Impact factor: 56.272

4.  The nonluteal porcine ovary as a source of angiogenic activity.

Authors:  A Makris; K J Ryan; T Yasumizu; C L Hill; B R Zetter
Journal:  Endocrinology       Date:  1984-11       Impact factor: 4.736

5.  A light microscopic study of the effects of testicular hyaluronidase on the outflow system of a baboon (Papio cynocephalus).

Authors:  I Grierson; W R Lee; S Abraham
Journal:  Invest Ophthalmol Vis Sci       Date:  1979-04       Impact factor: 4.799

6.  Ocular hypotony following retinal vein occlusion.

Authors:  S S Hayreh; W March; C D Phelps
Journal:  Arch Ophthalmol       Date:  1978-05

7.  Weibel-Palade bodies as a marker for neovascularization induced by tumor and rheumatoid angiogenesis factors.

Authors:  P Kumar; A Erroi; A Sattar; S Kumar
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

8.  Ocular neovascularization with retinal vascular occlusion. I. Association with experimental retinal vein occlusion.

Authors:  P S Virdi; S S Hayreh
Journal:  Arch Ophthalmol       Date:  1982-02

Review 9.  Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion.

Authors:  S S Hayreh; P Rojas; P Podhajsky; P Montague; R F Woolson
Journal:  Ophthalmology       Date:  1983-05       Impact factor: 12.079

10.  Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants.

Authors:  D BenEzra
Journal:  Am J Ophthalmol       Date:  1978-10       Impact factor: 5.258

View more
  2 in total

1.  Capillary endothelial-cell mitogenic activity in experimental branch vein occlusion.

Authors:  E de Juan; E Stefánsson; J S Dickson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 2.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.